HDL in the 100s is NOT reliably cardioprotective and may paradoxically increase cardiovascular risk.
While traditional thinking held that higher HDL cholesterol (HDL-C) is universally protective, recent high-quality evidence demonstrates a U-shaped relationship between HDL-C and cardiovascular outcomes—meaning very high HDL-C levels (≥100 mg/dL in women, ≥80 mg/dL in men) are associated with increased mortality and cardiovascular events, not protection.
The Evidence Against Universal Protection
The most recent and robust research directly challenges the "higher is better" HDL paradigm:
A 2022 prospective cohort study of nearly 20,000 patients with established coronary artery disease found that very high HDL-C levels (>80 mg/dL) were associated with a 96% increased risk of all-cause death and 71% increased risk of cardiovascular death compared to midrange values (40-60 mg/dL) 1. This association persisted even after adjusting for genetic factors that influence HDL-C levels.
A 2025 Korean study of over 810,000 healthy adults confirmed this U-shaped relationship, showing that HDL-C ≥60 mg/dL was associated with increased hemorrhagic stroke risk (HR 1.13) and higher all-cause mortality despite lower ischemic heart disease risk 2.
A 2024 comprehensive review emphasizes that mendelian randomization studies indicate HDL-C is unlikely to be a direct biologic variable impacting cardiovascular risk, and that very high HDL-C (≥80 mg/dL in men, ≥100 mg/dL in women) is paradoxically associated with higher mortality 3.
Why Guidelines Focus on Optimal Ranges, Not Maximum Levels
Current cardiovascular prevention guidelines consistently recommend target HDL-C levels above minimum thresholds, not maximization:
- The 2007 AHA guidelines for women recommend HDL-C >50 mg/dL as optimal, not levels in the 100s 4
- The 2004 AHA/ACC guidelines recommend raising HDL-C to >40 mg/dL (>50 mg/dL in women), again focusing on minimum protective levels 5
- The 2019 ACC/AHA primary prevention guidelines list low HDL-C (<40 mg/dL in men, <50 mg/dL in women) as a risk-enhancing factor, but do not suggest that extremely high HDL-C provides additional protection 6
Clinical Implications for Your Patient
If your patient has HDL-C in the 100s:
Do not assume they are protected from cardiovascular disease. Perform comprehensive risk assessment using established tools (10-year ASCVD risk calculator, coronary artery calcium scoring if indicated).
Evaluate for other cardiovascular risk factors that may be masked by the falsely reassuring high HDL-C number:
Focus treatment on proven interventions:
Do NOT use therapies aimed at raising HDL-C further. Multiple trials with niacin, fibrates, and CETP inhibitors have failed to show cardiovascular benefit when added to statin therapy, despite raising HDL-C 3, 11.
Common Pitfalls to Avoid
Assuming high HDL-C negates other risk factors: The evidence shows HDL-C in the 100s does not override the importance of LDL-C control, blood pressure management, or other established risk factors.
Using HDL-C as a treatment target: Guidelines consistently emphasize that HDL-C is a risk marker, not a treatment target 10, 11. The 2013 ACC/AHA cholesterol guidelines explicitly moved away from HDL-C targets.
Overlooking the sex difference: The increased mortality risk with very high HDL-C appears more pronounced in men than women 1.
The Bottom Line
HDL-C in the 100s should prompt standard cardiovascular risk assessment, not reassurance. Focus on evidence-based interventions: LDL-C lowering with statins, blood pressure control, lifestyle modification, and appropriate antiplatelet therapy. The patient's overall cardiovascular risk profile—not their HDL-C number—should guide management decisions.